Toradol

Critical Warnings, Restrictions And Patient Protection (Australia)

Basic Toradol Information

• INN (International Nonproprietary Name): Ketorolac Tromethamine
• Brand Names Available In Australia: Toradol and generic ketorolac (tablets and injection)
• ATC Code: M01AB15
• Forms & Dosages: Tablet 10 mg; Injection 10 mg/mL and 30 mg/mL; Eye drops 0.5% (Acular internationally)
• Manufacturers In Australia: International manufacturers include Hoffmann‑La Roche (Toradol), Sandoz, Teva, Pfizer, Mylan; local supply generally via generic suppliers
• Registration Status In Australia: Widely registered with Rx‑only status
• OTC / Rx Classification: Prescription‑only (Rx) in Australia

Are you worried about safety straight away?

Ketorolac (Toradol) can cause serious harm in the wrong patient or the wrong setting.

Absolute contraindications include active gastrointestinal bleeding, known severe renal failure, hypersensitivity to NSAIDs, and use in the third trimester of pregnancy.

Maximum recommended duration for oral or parenteral use is five days or less.

Breastfeeding and labour are not appropriate situations for ketorolac use.

Elderly patients need special caution because adverse events occur more frequently.

Key drug interactions to watch are anticoagulants and ACE inhibitors among others.

• Stop the drug and seek emergency care for signs of gastrointestinal bleeding, anaphylaxis, severe dizziness or reduced urine output.
• Baseline renal function and a full medication review are advised before supply.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Which patients are higher risk?

Elderly people, pregnant women, and those with chronic kidney, liver or cardiac disease face altered pharmacokinetics and higher adverse event rates.

Ketorolac should be avoided or dose‑reduced in renal impairment, and used with caution in hepatic impairment.

In many high‑risk cases, referral to a consultant or hospital review is recommended before use.

• Pre‑treatment renal check (eGFR or creatinine)
• Current anticoagulant or NSAID use
• Pregnancy status confirmed
• History of asthma or NSAID sensitivity

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Dizziness and drowsiness are recognised adverse effects with ketorolac.

Do not drive or operate heavy machinery until you know how ketorolac affects you.

Australian road safety and workplace health and safety obligations require alertness; impairment from medication can be a legal risk.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: No until you know how it affects you.

If you experience dizziness, drowsiness, blurred vision or confusion, do not drive.

Usage Basics: Names, Legal Status And Australian Availability

INN, Brand Names Available In Australia

What names will you see on a prescription?

The INN is ketorolac tromethamine.

Australian brand examples include Toradol and generic ketorolac preparations in tablet and injectable forms.

An ocular product (Acular) exists internationally, but ophthalmic use is a different formulation to systemic ketorolac.

Legal Classification (TGA‑Approved, PBS‑Listed)

Ketorolac/Toradol is prescription‑only under TGA regulation in Australia.

Many parenteral uses occur in hospital settings and PBS subsidy varies by product and indication.

Prescribers should check PBS listings case‑by‑case when considering outpatient subsidy.

• Telehealth prescriptions are accepted if the clinician documents the indication.
• Pharmacists must verify supply against TGA guidance and the patient’s medications.

Dosing Guide And Special Adjustments

Standard Regimens (PBS Reference Dosing)

What dose do adults typically get?

Adults: oral 10 mg every 4–6 hours as needed.

Parenteral dosing is commonly 10–30 mg IM/IV every 6 hours depending on severity and setting.

Maximum duration of oral or parenteral therapy is five days or less.

Some clinicians use a single IM/IV 30 mg dose for severe migraine as an off‑label option; monitoring is required.

Adjustments For Comorbidities

How do comorbidities change the plan?

Elderly patients should receive the lowest effective dose, often 10 mg, and for the shortest possible time.

Renal impairment: avoid ketorolac in significant renal dysfunction and do not use in severe renal failure.

Hepatic impairment: use caution, monitor liver function tests and consider dose reduction.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember unless the next scheduled dose is near.

Do not double up doses to make up for a missed one.

Contact a pharmacist or GP if unsure about timing or safety.

q4–6h

Every four to six hours.

IM

Intramuscular injection.

IV

Intravenous injection.

Single‑dose vs Maintenance

Single high parenteral dose may be used for acute severe pain; maintenance is short term only (≤5 days).

Interaction Chart: Drugs, Food And Alcohol

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Can you drink alcohol while taking ketorolac?

Alcohol increases the risk of gastrointestinal bleeding when combined with NSAIDs.

Advise patients who commonly consume alcohol to avoid alcohol while taking ketorolac.

Caffeine does not have a major pharmacokinetic interaction but may mask dizziness or jitteriness.

Common Drug Conflicts

Which drugs confer the biggest risks?

• Perform medication reconciliation before supply.
• Counsel patients on signs of bleeding and renal impairment.
• Liaise with the prescriber to consider safer alternatives when interaction risk is high.

Practical Pharmacy Screening Checklist

• Current use of anticoagulant or antiplatelet medicines?
• Concurrent SSRI/SNRI therapy?
• ACE inhibitor, ARB or diuretic use?
• Any other NSAID or aspirin use today?
• Recent renal function tests available?

User Reports, Australian Patient Trends And Safety Signals

What do Australian patients say about toradol?

• Common complaints in consumer feedback are nausea, dizziness and gastrointestinal upset.
• Serious reports include gastrointestinal bleeding and renal issues, echoed in regional forums and product reviews.
• Many patients expect rapid relief after parenteral administration and can be disappointed by the five‑day limit.
• Price sensitivity is common and people often seek pharmacist advice before use.
• Rural patients describe delayed access to monitoring labs and patchy follow‑up after telehealth prescriptions.

Recommended safety signals to monitor at home include increased dizziness, decreased urine output and black or tarry stools.

Escalate any of those findings to emergency care immediately.

Access And Purchase Options In Australia

National Chains And Community Pharmacies

Where can you get toradol in Australia?

Major outlets such as Chemist Warehouse, Priceline and TerryWhite Chemmart dispense prescribed toradol when a valid prescription is provided.

Many stores offer pharmacist consultations for NSAID counselling and screening.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth e‑prescriptions are accepted by reputable pharmacies.

Online pharmacies typically require a valid script and may courier prescriptions to patients.

In our online pharmacy, toradol is available without a prescription, with discreet delivery to Australia in 9-21 days.

Remember some injectable formulations are administered only in hospital or clinic because they need trained staff.

Mechanism Of Action And Pharmacology (Simplified And Clinical)

Simplified Explanation

How does ketorolac relieve pain?

Ketorolac is a non‑selective NSAID that inhibits both COX‑1 and COX‑2 enzymes.

Inhibiting those enzymes reduces prostaglandin synthesis and produces potent analgesia and anti‑inflammatory effect.

The analgesic potency can be comparable to low‑dose opioids in acute settings, which explains its place in post‑operative pain management.

Clinical Pharmacology Terms

Onset is rapid with parenteral administration and slower with oral dosing.

Elimination is primarily renal, so kidney function is critical to safe use.

Half‑life and metabolism considerations support dosing every 4–6 hours orally or every 6 hours parenterally.

Onset

Parenteral: rapid; Oral: slower.

Elimination

Renal excretion predominates; avoid in severe renal impairment.

Potency

High analgesic effect but higher risk profile than many OTC NSAIDs.

Indications And Common Off‑Label Uses In Australian Practice

Approved Indications By TGA

What is ketorolac approved for?

Primary approved use is short‑term management of moderate to severe acute pain, often post‑operative.

Both parenteral and oral formulations are used depending on the clinical setting.

Off‑Label Uses In Australian Clinical Practice

Common off‑label examples include single‑dose IM/IV ketorolac for severe migraine abortive therapy.

Ophthalmic NSAID formulations are used for post‑operative ocular inflammation, but those are distinct products.

Off‑label parenteral use in the community must weigh renal and GI risk and the ability to monitor the patient.

• Common indications: post‑operative pain, acute severe pain in ED or perioperative settings.
• Off‑label uses: single IM/IV dose for severe migraine; community use must be justified and documented.

• Checklist For Clinician Justification: document indication, confirm renal function, explain duration limit, follow up plan.

Key Clinical Findings And Safety Evidence 2022–2026 (Select Overview)

What does recent evidence say at a glance?

• Efficacy outcomes: ketorolac consistently provides effective short‑term analgesia, especially parenterally.
• Safety outcomes: elevated risks of gastrointestinal bleeding and renal impairment are consistently reported.
• Regulatory actions: ketorolac was withdrawn from some markets historically due to GI/renal safety signals.
• Clinical implications: strict duration limits (≤5 days), renal screening, and careful patient selection are standard in ED and anaesthesia protocols.

Readers should consult the TGA monograph and local hospital analgesic policies for full details and current systematic reviews for deeper evidence summaries.

Alternatives Matrix And Pros/Cons Checklist

PBS‑Listed Alternatives Comparison Table

Pros And Cons Checklist

• Pros Of Ketorolac: potent short‑term analgesia, effective IV/IM in acute settings.
• Cons: maximum five‑day limit, higher GI and renal risk, prescription‑only and contraindicated in pregnancy and renal failure.
• Decision Aid: prefer alternatives for elderly, anticoagulated patients, or those with chronic renal disease.

Common Questions From Australian Pharmacy Consultations (Top FAQs)

• “Is it safe to take with my blood thinner?” — Generally not recommended; liaise with the prescriber before supply.
• “How long can I take Toradol?” — Maximum five days for oral or parenteral use.
• “Can children take it?” — Rarely used; dosing is weight‑based and specialist advice is recommended.
• “Will it affect my kidneys?” — Ketorolac carries renal risk; avoid in renal impairment and arrange renal function checks if risk factors exist.
• “What are the emergency signs?” — Black stools, severe abdominal pain, reduced urine output, severe breathlessness, or suspected anaphylaxis require immediate GP or ED review.

Pharmacists are advised to document counselling and, where necessary, use referral forms to notify prescribers of concerns.

Price And Access Comparison (Pharmacy/Source Table)

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Access Checklist — Major Chains, Online Pharmacies, Rural Versus Urban Availability

• Valid prescription required for lawful supply in Australia.
• Injectable forms are often administered in clinic or hospital settings only.
• Check PBS schedule for current subsidy before advising a patient about cost.
• Courier delivery options exist for remote patients but expect longer transit times and follow‑up challenges.

Registration, Regulation And Prescribing Rules (TGA & PBS)

TGA Approval

Ketorolac/Toradol is TGA‑registered as a prescription‑only medicine in Australia.

Local product labelling and approved indications should be followed at all times.

PBS Subsidy Details

PBS listings and subsidy status are product‑specific and indication‑dependent.

Some hospital uses may be unfunded in outpatient settings.

Prescribers must check the PBS schedule for up‑to‑date subsidy criteria for the specific product.

• Registration: confirm product is TGA registered.
• Labelling: follow local product labelling and contraindications.
• PBS Check: verify subsidy criteria before advising on cost.
• Documentation: retain clear indication and follow‑up instructions for patient records.

Storage, Transport And Handling (Home And Pharmacy)

Household Storage In Australian Climate (Heat/Humidity)

How should patients store toradol at home?

Store tablets and injectables at room temperature, typically 15–25°C, protecting from moisture and light.

Do not freeze injectables.

In hot or humid regions, keep the product in a cool, dry cupboard away from direct sunlight.

Discard any product if packaging or product integrity is compromised.

Cold‑Chain Handling For Pharmacies

Most ketorolac injectables are stable at room temperature, but follow the manufacturer’s storage instructions.

Prepare IV or IM doses using aseptic technique to avoid contamination.

• Storage Temperatures: 15–25°C unless otherwise specified.
• Transport Advice: carry in original packaging with prescription documentation.
• Patient Counselling Points: keep out of reach of children; store away from heat and humidity.

Guidelines For Proper Use And Australian Pharmacist Counselling

Australian Pharmacist Counselling Style

What should pharmacists tell patients in plain language?

Explain the indication and the short‑term use limit of five days or less.

Discuss gastrointestinal and renal risks and the symptoms that require urgent review.

Review all current medicines including anticoagulants, ACE inhibitors, diuretics and SSRIs.

Advise complete avoidance of alcohol while taking ketorolac.

Provide a written action plan that clarifies when to stop the drug and when to see a GP or go to ED.

Patient Advice From PBS And National Health Authorities

Reinforce adherence to the prescriber’s instructions and the prohibition on combining ketorolac with other NSAIDs or aspirin unless directed.

Encourage patients with risk factors to arrange a renal function test before treatment when possible.

• Check renal function in at‑risk patients before supply.
• Advise to stop medication and seek urgent care for black stools, severe abdominal pain, breathlessness, or decreased urine output.
• Document counselling in the patient record and provide a short patient leaflet with key warnings.

• Patient Leaflet Template (Bullets)
• Take as prescribed; maximum five days.
• Do not mix with other NSAIDs or alcohol.
• Contact GP or ED for bleeding, severe abdominal pain, or low urine output.

Delivery Across Australia